vTv Therapeutics Inc. — Q1 2023 Form 10-Q
Business context and period: Unaudited results for the three months ended March 31, 2023, compared with Q1 2022. vTv is a clinical-stage pharmaceutical company focused on metabolic and inflammatory diseases; its lead program is TTP399 for type 1 diabetes. It has not generated product revenue.
Financial results and liquidity
| Metric | Q1 2023 | Q1 2022 / prior date |
|---|---|---|
| Revenue | $0 | $2.0 million |
| Research and development | $3.9 million | $3.1 million |
| General and administrative | $3.5 million | $5.3 million |
| Operating loss | $7.4 million | $6.5 million |
| Net loss attributable to vTv Therapeutics Inc. | $4.5 million | $7.0 million |
| Basic and diluted loss per Class A share | $0.06 | $0.10 |
| Cash and cash equivalents | $18.8 million | $12.1 million at Dec. 31, 2022 |
| Long-term investments | $7.7 million | $5.6 million at Dec. 31, 2022 |
| Net cash used in operating activities | $5.2 million | $1.0 million |
| Total liabilities | $28.4 million | $27.4 million at Dec. 31, 2022 |
Operating expenses totaled $7.4 million, down from $8.5 million. R&D spending rose 25.8%, primarily from TTP399 drug-product costs and other research activity; G&A fell 34.8%, mainly due to lower legal and severance costs. Q1 2022 revenue reflected a $2.0 million Huadong-related milestone accounting adjustment; no revenue was recognized in Q1 2023. Q1 2023 other income was substantially supported by a $2.1 million unrealized gain on Reneo shares, partly offset by warrant remeasurement and a $0.3 million loss from early collection of the G42 note.
Cash increased by $6.6 million, primarily because vTv received $12.0 million from early redemption of G42’s promissory note; this was financing cash flow, not operating cash generation. Current assets were $20.6 million and current liabilities $8.5 million. Notes payable were nil, versus $0.2 million at year-end. Contract liabilities were $18.7 million. The company reported an accumulated deficit of $274.3 million and stockholders’ deficit of $19.2 million.
Material changes, outlook, and risks
- Management estimates current cash and cash equivalents will fund operations into Q3 2023. It is evaluating equity financing, licensing or monetizing programs, and partnering opportunities to fund operations and TTP399 development into Q1 2024. The timing and availability of financing are uncertain.
- The filing states that recurring losses, cash needs, and dependence on additional funding raise substantial doubt about the company’s ability to continue as a going concern. ATM and Lincoln Park share-sale capacity is available, but use depends in part on the stock price and trading volume and could dilute shareholders.
- Management expects to initiate TTP399 study activities in the second half of 2023. The FDA agreed to the pediatric study plan and to the proposed primary endpoint: reduction in hypoglycemic events. Trial timing, enrollment, results, regulatory decisions, and funding remain uncertain.
- Under the G42 transaction, FDA approval of TTP399 could trigger, at G42’s option and subject to contractual conditions, either $30 million in Class A shares or a $30 million cash payment by the company. The G42-related $18.7 million deferred revenue balance remained unrecognized because performance obligations had not been satisfied.
- Potential Novo Nordisk development, regulatory, and sales milestones and royalties remain contingent on future events. The company reported no material legal proceedings and no material changes to previously disclosed risk factors.
Investor verification priorities
- Confirm current cash runway and whether financing or partnering transactions have closed since the May 11, 2023 filing date.
- Track TTP399 trial initiation, enrollment, clinical results, and regulatory milestones against the stated plans.
- Review any ATM or Lincoln Park share sales for proceeds, dilution, and remaining capacity.
- Assess the terms and potential cash or dilution impact of the contingent G42 FDA-approval payment and the company’s other contractual obligations.
- Distinguish recurring operating cash burn from investment fair-value movements and one-time note-redemption proceeds when assessing liquidity.